Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
Xue Yang, Jiao Li, Xiaoyi Li, et al.
Journal of Nuclear Medicine (2016) Vol. 58, Iss. 2, pp. 258-265
Open Access | Times Cited: 108

Showing 1-25 of 108 citing articles:

Genomic alterations in thyroid cancer: biological and clinical insights
Iñigo Landa, Maria E. Cabanillas
Nature Reviews Endocrinology (2023) Vol. 20, Iss. 2, pp. 93-110
Closed Access | Times Cited: 43
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease
Miguel Melo, Adriana Gaspar da Rocha, Rui Batısta, et al.
The Journal of Clinical Endocrinology & Metabolism (2017) Vol. 102, Iss. 6, pp. 1898-1907
Open Access | Times Cited: 125
Telomere Maintenance Mechanisms in Cancer
Tiago Bordeira Gaspar, Ana Sá, José Manuel Lopes, et al.
Genes (2018) Vol. 9, Iss. 5, pp. 241-241
Open Access | Times Cited: 113
The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
Jiajun Liu, Rengyun Liu, Xiaopei Shen, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 2, pp. 177-182
Open Access | Times Cited: 104
Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
Jie-Rui Liu, Yanqing Liu, Yansong Lin, et al.
Endocrinology and Metabolism (2019) Vol. 34, Iss. 3, pp. 215-215
Open Access | Times Cited: 101
Redifferentiation of radioiodine-refractory thyroid cancers
Camille Buffet, Johanna Wassermann, Fábio Hecht, et al.
Endocrine Related Cancer (2020) Vol. 27, Iss. 5, pp. R113-R132
Open Access | Times Cited: 77
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
Mohammad Al-Jundi, Shilpa Thakur, Sriram Gubbi, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2104-2104
Open Access | Times Cited: 73
Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
Yujia Liu, Jiafeng Wang, Xiao Hu, et al.
Drug Resistance Updates (2023) Vol. 68, pp. 100939-100939
Open Access | Times Cited: 33
Risk stratification for radioactive iodine refractoriness using molecular alterations in distant metastatic differentiated thyroid cancer
Zhuanzhuan Mu, Xin Zhang, Dongquan Liang, et al.
Chinese Journal of Cancer Research (2024) Vol. 36, Iss. 1, pp. 25-35
Open Access | Times Cited: 9
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
Jing Yang, Yanping Gong, Shuping Yan, et al.
Endocrine (2019) Vol. 67, Iss. 1, pp. 44-57
Open Access | Times Cited: 70
Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status
Louise Schubert, A. M. Mbekwe-Yepnang, Johanna Wassermann, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 6, pp. 1573-1581
Open Access | Times Cited: 7
Genomic Hallmarks of Thyroid Neoplasia
Thomas J. Giordano
Annual Review of Pathology Mechanisms of Disease (2017) Vol. 13, Iss. 1, pp. 141-162
Open Access | Times Cited: 57
Genetic-guided Risk Assessment and Management of Thyroid Cancer
Mingzhao Xing
Endocrinology and Metabolism Clinics of North America (2019) Vol. 48, Iss. 1, pp. 109-124
Open Access | Times Cited: 50
Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review
Brittany A. McKelvey, Christopher B. Umbricht, Martha A. Zeiger
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 46
The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer
Jingjia Cao, Xiaolu Zhu, Yaru Sun, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 49, Iss. 10, pp. 3470-3481
Closed Access | Times Cited: 25
<i>TERT</i> promoter mutations in thyroid cancer
Michiko Matsuse, Norisato Mitsutake
Endocrine Journal (2023) Vol. 70, Iss. 11, pp. 1035-1049
Open Access | Times Cited: 14
Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma
Merel T Stegenga, Evert F.S. van Velsen, Lindsey Oudijk, et al.
The Journal of Clinical Endocrinology & Metabolism (2024) Vol. 109, Iss. 12, pp. e2334-e2341
Open Access | Times Cited: 5
Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations
Tae Hyuk Kim, Chang‐Seok Ki, Hye Seung Kim, et al.
The Journal of Clinical Endocrinology & Metabolism (2017) Vol. 102, Iss. 5, pp. 1757-1764
Open Access | Times Cited: 44
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases
Cristina Romei, Raffaele Ciampi, Francesca Casella, et al.
Oncotarget (2018) Vol. 9, Iss. 11, pp. 9875-9884
Open Access | Times Cited: 44
<i>BRAF</i> and <i>TERT</i> promoter mutations: clinical application in thyroid cancer
Jae Hoon Chung
Endocrine Journal (2020) Vol. 67, Iss. 6, pp. 577-584
Open Access | Times Cited: 39
Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Yi Luo, Hongyi Jiang, Weibo Xu, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 36
The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
Carla Colombo, Emanuela Minna, Chiara Gargiuli, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 36
Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance
Huize Shen, Rui Zhu, Yanyang Liu, et al.
Drug Resistance Updates (2023) Vol. 72, pp. 101013-101013
Open Access | Times Cited: 12
Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer
Ye Sang, Guanghui Hu, Junyu Xue, et al.
Endocrine (2024) Vol. 85, Iss. 1, pp. 304-312
Closed Access | Times Cited: 4
Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers
Abdul Rehman Syed, Aakash Gorana, Erik Nohr, et al.
European Thyroid Journal (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top